Amphetamine-Related Disorders Clinical Trial
Official title:
Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM: a 6-month Randomized Controlled Trial With 3 Months of Follow-up
The investigators recently conducted a double-blind, randomized controlled trial (n=60) of limited duration (12 weeks), and found that compared with placebo, oral mirtazapine, an FDA-approved antidepressant, significantly reduced meth use in those receiving mirtazapine, as determined by reduction in meth-positive urines. Sexual risk behaviors also declined significantly in the mirtazapine arm compared to placebo. Mirtazapine decreased meth use despite low adherence: by medical event monitoring system (MEMS) caps, only 48.5% of daily doses were taken. All participants received weekly substance use counseling and monthly, brief clinician-delivered adherence counseling. The investigators propose expanding upon these results by lengthening the treatment period to 24 weeks, with adherence reminders added to the counseling, and determining if efficacy is sustained up to 12 weeks after drug discontinuation. The sample size for this 9-month study is 120.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02232789 -
Abuse Liability and Human Pharmacology of Mephedrone
|
Phase 1 | |
| Completed |
NCT01449565 -
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
|
Phase 2 | |
| Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
| Active, not recruiting |
NCT00100074 -
To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00033072 -
Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
|
Phase 1 | |
| Recruiting |
NCT06145698 -
Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD
|
N/A | |
| Completed |
NCT00990067 -
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)
|
Phase 1 | |
| Completed |
NCT02797990 -
Conflict Between Maternal Autonomy and Child Health in Substance-use
|
N/A | |
| Recruiting |
NCT01899313 -
A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence
|
N/A | |
| Active, not recruiting |
NCT00265278 -
Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00000350 -
Effects of Stimulant Dependence on Human Striatal Dopamine System - 15
|
Phase 1 | |
| Active, not recruiting |
NCT00089440 -
Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00040040 -
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
|
Phase 1 | |
| Completed |
NCT00040053 -
Ondansetron for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 | |
| Completed |
NCT00895804 -
Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)
|
Phase 1 | |
| Recruiting |
NCT03902405 -
Computerized Exercise to Alter Stimulant Approach Responses
|
N/A | |
| Recruiting |
NCT04982796 -
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
|
Phase 1/Phase 2 | |
| Completed |
NCT01386177 -
Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
| Completed |
NCT01136278 -
Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
| Completed |
NCT00069251 -
Bupropion for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 |